NCT02222740View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
Osteoarthrosis
Interventions
DRUG

10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)

Schedule II Class

DRUG

20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)

Schedule II Class

All Listed Sponsors
lead

Zogenix, Inc.

INDUSTRY

NCT02222740 - A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain | Biotech Hunter | Biotech Hunter